Fischer Medical Ventures Ltd (FISCHER) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Fischer Medical Ventures Ltd ₹5.03, price ₹33.50, upside -85.0%, quality 43 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 2, 2026.
How to read this chart
60‑month range ₹1.31 – ₹117.65 · fair‑value band ₹3.39 – ₹8.19 · the ₹33.50 price screens above the ₹5.03 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 2, 2026.
Follow Fischer Medical Ventures in your weekly email
Every Wednesday you see whether Fischer Medical Ventures is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Fischer Chemic Limited trades in laboratory chemicals and machineries in India. It also provides AMC and consultancy services. The company was incorporated in 1993 and is based in Mumbai, India.
Stock analysis
Fischer Medical Ventures Ltd (FISCHER) currently trades at ₹33.50, while our model-based Fair Value estimate is ₹5.03, 85.0% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹20.75 per share, and 0 of the 17 models we run sit above the ₹33.50 price.
Bear case: the Asset-Based group reads lowest at ₹3.76, and 17 of the 17 models stay below the price. Evidence for this calculation is low.
Scenario range: ₹3.39 (bear) to ₹8.19 (bull), the price of ₹33.50 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 43/100 (below-average quality), in the Industrials sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Fischer Medical Ventures Ltd reported revenue of ₹3.1B in FY2026 versus ₹0 in FY2022. Reported net income was ₹310M in FY2026.
Key figures
Market cap ₹21.9B (≈ $228M) · P/E ratio 74.4 · P/S ratio 7.48 · EPS (TTM) ₹0.4500 · Dividend yield 0.1% · Net margin 10.1% · Return on equity 8.6% · Return on assets (EBIT) −17.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 72% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Industrials peers we cover trades at 49% fair-value upside, at −85%, FISCHER screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (₹0.0400 to ₹21.49). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear ₹3.39Fair Value ₹5.03Bull ₹8.19
Price ₹33.50 · Upside -85.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹0.2060 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.46/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+178.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1,097.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+351.2%
Start year 2021 (pandemic). Over 10 years: +125.8% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+109.1%
’14
’15
’16
’20
’21
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−44.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year−44.2%
Dividend (yield on the price)0.1%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−11% → 13%
2026 sits 78% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Compare Fischer Medical Ventures Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Professional & Commercial Services · 16 stocks
Beats the industry median on 3/8 measures
Overall it trails its industry peers.
Valuation
Quality Score43 · Bottom 25%
Fair Value upside−85.0% · Bottom 25%
Profitability
Return on assets4.4% · Below median
Net margin (TTM)8.2% · Above median
Operating margin (TTM)12.1% · Below median
Growth and dividend
Revenue growth249.4% · Top 25%
Dividend yield (TTM)0.1% · Bottom 25%
Balance sheet
Debt / equity0.00× · Below median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 68
FUTURE (revenue growth)100· sector 8
PAST (return on equity)35· sector 0
HEALTH (low debt)100· sector 100
DIVIDEND (yield)3· sector 58
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Fischer Medical Ventures Ltd Fair Value". https://www.fairvalue-calculator.com/stock/FISCHER
Frequently asked questions
Is Fischer Medical Ventures Ltd (FISCHER) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of ₹5.03 versus a price of ₹33.50, about −85% upside (overvalued).
What is the fair value of FISCHER?
Our model-based fair value for Fischer Medical Ventures Ltd is ₹5.03 (as of Oct 2, 2026), built from audited fundamentals. The current price: ₹33.50.
What is the quality score of FISCHER?
Fischer Medical Ventures Ltd has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Fischer Medical Ventures Ltd (FISCHER)?
Our model-based price target is the fair value of ₹5.03 (as of Oct 2, 2026) from 17 valuation models. Cautious scenario ₹3.39, optimistic scenario ₹8.19. It is a calculation from audited fundamentals, not an analyst target.
What is the Fischer Medical Ventures Ltd stock forecast for 2026?
Our models put fair value at ₹5.03, about −85% upside versus a price of ₹33.50 (overvalued). Cautious scenario ₹3.39, optimistic scenario ₹8.19. The calculation is refreshed regularly with new filings.
What is the revenue of Fischer Medical Ventures Ltd (FISCHER)?
Fischer Medical Ventures Ltd reported trailing-twelve-month revenue of about ₹3.7B (latest available figure, as of Oct 2, 2026).
Does Fischer Medical Ventures Ltd pay a dividend?
Fischer Medical Ventures Ltd currently shows a dividend yield of about 0.15% relative to its recent price (as of Oct 2, 2026).
What is the intrinsic value of Fischer Medical Ventures Ltd (FISCHER)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Fischer Medical Ventures Ltd it is ₹5.03 per share (as of Oct 2, 2026), against a price of ₹33.50. It is the blended result of 17 valuation models (cash flow, earnings, asset, dividend).
Is Fischer Medical Ventures Ltd stock overvalued or undervalued in 2026?
As of Oct 2, 2026, FISCHER trades above its calculated fair value: price ₹33.50, fair value ₹5.03, a gap of about −85% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of FISCHER?
No. The price is what the market pays today (₹33.50); the fair value is what the company's own numbers justify (₹5.03). For Fischer Medical Ventures Ltd the two are ₹28.47 per share apart. That gap is exactly why we show both numbers side by side.
How much is Fischer Medical Ventures Ltd worth?
The market values Fischer Medical Ventures Ltd at about ₹21.9B (market capitalisation, as of Oct 2, 2026). Per share that is ₹33.50; our models calculate a fair value of ₹5.03 per share.
What do the bullish and bearish scenarios say about FISCHER?
Our models span a range for Fischer Medical Ventures Ltd: cautious scenario ₹3.39, base ₹5.03, optimistic ₹8.19 per share (as of Oct 2, 2026, price ₹33.50). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of FISCHER?
Fischer Medical Ventures Ltd trades at a price-to-earnings ratio of 74.4 (as of Oct 2, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹5.03 is built from several models across several years. Other multiples: P/B 5.7, P/S 6.0, EV/EBITDA 45.0.
How solid is the balance sheet of Fischer Medical Ventures Ltd (FISCHER)?
Balance-sheet figures for Fischer Medical Ventures Ltd (as of Oct 2, 2026): return on equity 8.6%, debt of 0.00 per unit of equity. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is FISCHER from its 52-week high?
Fischer Medical Ventures Ltd trades at ₹33.50, about 72% below its 52-week high of ₹117.65 and 7% above the low of ₹31.34 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹5.03 is for.
Which stocks are comparable to Fischer Medical Ventures Ltd?
From the same area (Industrials) we also value e-Credible Co, KG Mobilians Co, INSUN Environmental New Technology Co, Nice D&B Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Fischer Medical Ventures Ltd stock attractive at the current price?
The data as of Oct 2, 2026: price ₹33.50, calculated fair value ₹5.03 (−85%), Quality Score 43/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of FISCHER calculated?
We run Fischer Medical Ventures Ltd through 17 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹5.03, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Fischer Medical Ventures Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Fischer Medical Ventures Ltd (FISCHER)?
The closing price on Oct 1, 2026 was ₹33.50. Our model-based fair value is ₹5.03, about −85% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Fischer Medical Ventures Ltd right now?
The price sits above even our optimistic bull case (₹8.19). The favourable scenario is already priced in. Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (₹3.39 to ₹8.19) leaves room in how you read the outcome.
Key figures of Fischer Medical Ventures Ltd
How large is the market capitalisation of Fischer Medical Ventures Ltd (FISCHER)?
The market capitalisation of Fischer Medical Ventures Ltd is ₹21.9B (≈ $228M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Fischer Medical Ventures Ltd (FISCHER)?
The price-to-sales ratio of Fischer Medical Ventures Ltd is 7.48 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Fischer Medical Ventures Ltd (FISCHER)?
Earnings per share at Fischer Medical Ventures Ltd are ₹0.4500 (price ÷ EPS = P/E 74.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Fischer Medical Ventures Ltd (FISCHER)?
The dividend yield of Fischer Medical Ventures Ltd is 0.1% (payout 11.1%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Fischer Medical Ventures Ltd (FISCHER)?
The net margin of Fischer Medical Ventures Ltd is 10.1% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Fischer Medical Ventures Ltd (FISCHER)?
The return on equity (ROE) of Fischer Medical Ventures Ltd is 8.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Fischer Medical Ventures Ltd (FISCHER)?
On an EBIT basis the return on assets of Fischer Medical Ventures Ltd is −17.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Fischer Medical Ventures Ltd (FISCHER)?
The operating margin of Fischer Medical Ventures Ltd is 12.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Fischer Medical Ventures Ltd (FISCHER)?
Revenue at Fischer Medical Ventures Ltd is growing +249% versus a year earlier (3y avg +1,098%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Fischer Medical Ventures Ltd (FISCHER)?
Earnings per share at Fischer Medical Ventures Ltd are growing +41.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Fischer Medical Ventures Ltd (FISCHER) generate?
The free cash flow of Fischer Medical Ventures Ltd is −₹1.0B (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Fischer Medical Ventures Ltd (FISCHER) carry?
The net debt of Fischer Medical Ventures Ltd is ₹605M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Fischer Medical Ventures Ltd in the live analysis
One click puts Fischer Medical Ventures Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
